A dose of reality on drug patents
By
Philip Stevens
Himalya Drug Company, Bangalore. AFP / Getty Images
Debates on how to improve healthcare in developing countries
often start from the same premise: patents can potentially raise drug
prices, so they should be abolished for better public health.
In the early 2000s this argument drove the campaign against patents
on HIV drugs in South Africa. This month, it anchors new NGO campaigns
against a proposed EU-India Free Trade Agreement and the Regional
Comprehensive Economic Partnership in Asia – both of which may include
heightened intellectual property provisions.
NGO disquiet about drug patents has even led to the creation of a UN
High Level panel on access to medicines, due to report its
recommendations in New York next month.
Such concerns may in fact be overblown. This is an implication of an
interesting new study by researchers at the University of Ottawa and
published in April by the World Intellectual Property Organization
(WIPO) in Geneva.
To better understand how patents impact access to medicines, the
researchers counted how many of the World Health Organization’s (WHO)
List of Essential Medicines are subject to patent protection in
developing countries. This list contains 375 or so medicines considered
most important by WHO experts.
It’s a hugely influential list, and one based purely on the clinical
usefulness of a medicine, not cost or patent status. Developing country
governments and large international donors use it to guide which
medicines they will procure.
The researchers checked national patent registries in developing
countries and double-checked with manufacturers. They found that patents
for 95% medicines on the list had expired.
Put simply, patents are not relevant to the vast majority of drugs typically used by physicians in developing countries.
Most of the remaining 5% of medicines – around 20 products – on the
WHO list with patent protection are for HIV/AIDS. But patent owners
either don’t register or enforce their patents in the poorest countries.
For middle-income countries, manufacturers often enter into voluntary
licensing deals with generic manufacturers to broaden access, meaning
there are cheap generic copies on the international market.
The one medicine with no generic equivalent is the cancer drug,
bevacizumab (marketed as Avastin by Swiss patent-owner Roche). This
modern so-called ‘biologic’ drug is used against many cancers, and works
by starving tumours of their blood supply through blocking a key
protein.
Patented or not, these biologic drugs are difficult for generic competitors to copy cheaply.
Unlike most drugs, which are chemically synthesised and made from
just a few molecules, biologic drugs are manufactured in living systems
such as plant or animal cells, and have complex molecular structures.
Their manufacture demands significant investment and technical know-how,
meaning such drugs will never be as cheap as, say, generic aspirin.
One implication of the study is that if patents were abolished
tomorrow it would make little difference to the cost or availability of
most medicines used in developing countries.
Even so, these medicines are frequently unavailable in public health systems.
In 2014, researchers at the University of Utrecht in the Netherlands
found that, on average, essential medicines are available in public
sector facilities in developing countries only 40% of the time.
While generic medicines are cheap to make with no royalties to pay,
they are still too costly for most people in developing countries.
One example from the WHO list is budesonide, commonly used by asthma
sufferers. A single inhaler costs a staggering 50 days wages in
Mozambique. In the US, one inhaler costs only $5 to $7 – around 30
minutes work on the median hourly wage.
The reasons behind the expense and scarcity of essential medicines in
developing countries are complex, but failures of governance loom
large.
Mark-ups along the distribution chain inflate the final price of
medicines and include import tariffs, sales taxes, value-added taxes and
retailers’ and wholesalers’ margins. In Kenya, mark-ups add 300% to the
manufacturer’s price; in Brazil it’s 200%, says IMS, the global
healthcare data provider.
Dysfunctional medicine supply chain management is another culprit. A
2015 survey by humanitarian NGO Medecins Sans Frontières reported one in
three health facilities in South Africa have shortages of key HIV and
tuberculosis drugs. The drugs are imported in sufficient quantities but
fail to reach patients due to “local logistical and management problems,
ranging from inaccurate forecasting to storage or transport issues”,
said MSF.
Governments under-invest in health too. While most European Union
countries commit 8% to 11% of GDP to health, few Asian and African
countries spend more than 5%: not nearly enough given their enormous
health challenges.
These are the major influences on access to medicines. Public health
would be best served if the political focus were on these issues, rather
than patents.
Philip Stevens is director of Geneva Network, a research organization focusing on health, intellectual property and trade.
This article is an exclusive for CapX, and is available for syndication. Please contact
editors@capx.co to discuss details.
